Humira biosimilars

Jefferies remains bullish on AbbVie Inc (NYSE: ABBV) as management meetings suggest the next 12 months should see significant visibility emerge for its rheumatoid arthritis drug Humira biosimilars with the earliest potential U.S. launches only being seen post-2020. The brokerage reiterated its Buy...